Happy Monday, folks. This is Meghana of Team Readout subbing in for Ed in today’s edition of Pharmalot. Sprinkled between blaring headlines of last night’s epic Oscar flub, here are some pharma standouts:
Drug pricing is proving a touch more contained this year, with only a handful of medications seeing increases greater than 10 percent. The median drug pricing increase was largely unchanged, of course — clocking in at 8.9 percent, which is much higher than the US inflation rate of about 2 percent, as the Wall Street Journal points out. But this January, when pharma prices typically increase, pharma companies raised the prices of 5.5 percent of their drugs more than 10 percent, as opposed to 15.5 percent that did so last year and more than 20 percent the year before that.
Stock for La Jolla Pharmaceutical rocketed Monday morning — up more than 50 percent after the company released positive Phase 3 trial results for its hypotension treatment, according to MarketWatch. The results look rather lovely, statistically: While 23 percent of placebo-treated patients had improved blood pressure, about 70 percent of the patients treated with LJP’s drug showed that their high-output shock was normalized.
About the Author Reprints
